In the past 12‑18 months the Plant Peptone market has accelerated through strategic collaborations and capital infusions that reshape supply chains. Novus Biotech partnered with GreenLeaf Fermentation to co‑develop a low‑temperature enzymatic hydrolysis platform, promising higher yields for vegan media. Meanwhile, AgriPure acquired BioSynth Labs for $210 million, adding proprietary plant‑based peptide libraries to its portfolio. The launch of EcoPept™ 2.0, a gluten‑free, chemically‑defined peptone, has been touted as a breakthrough for cell‑culture bioprocessing, especially in the growing biologics‑manufacturing sector. Regulatory momentum accelerated when the EU revised its Novel Food guidelines in early 2024, granting faster review pathways for plant‑derived hydrolysates. Consumer demand for animal‑free ingredients continues to surge, driving biotech firms to prioritize sustainable protein sources. Recent Series B funding of $45 million to TerraPept underpins expansion of its pilot plant in Singapore, positioning the company for Asia‑Pacific growth. Enterprises are increasingly integrating plant peptones into serum‑free media to meet ESG goals, a move reflected in the 2024 Global Bioprocess Survey. These dynamics underscore the evolving Plant Peptone industry trends, signaling a trajectory toward broader adoption and sustained revenue expansion.
